Biogen Inc. (BIIB) News
Track canonical SquawkNews coverage tagged to BIIB, Biogen Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 44 indexed stories across 24 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
AI-based drug developer Basecamp valued at $800 million after $140 million funding round
By Puyaan SinghBasecamp Research said on Wednesday it has raised $140 million in a Series C funding round that valued the AI-based drug developer at $800 million.The oversubscribed round was led by S32, with participatio
NEWS | Sep 23, 2026, 01:00 PM UTC
M
LEQEMBI Pen approved in Japan for early Alzheimer’s
Eisai and Biogen said Japan approved LEQEMBI Pen, the subcutaneous formulation of lecanemab, for early Alzheimer’s disease treatment.
REGULATION | Sep 18, 2026, 03:44 PM UTC
M
Eisai and Biogen announce Japan approval of LEQEMBI Pen
Eisai and Biogen said Japan approved “LEQEMBI Pen,” a subcutaneous formulation for early Alzheimer’s disease.
REGULATION | Sep 16, 2026, 06:01 AM UTC
L
Biogen price target raised to $175 from $165 by HSBC
HSBC raised its Biogen price target to $175.00 per share from $165.00, according to Ratings actions reported by Benzinga (TradingView News).
EQUITY | Sep 10, 2026, 02:19 PM UTC
L
BIIB: Diversification, disciplined investment, and pipeline execution drive growth and resilience
Management highlighted strategic diversification beyond neurology, disciplined capital allocation, and operational efficiency. Key growth drivers include a robust late-stage pipeline, expansion into nephrology and immuno
EQUITY | Sep 09, 2026, 02:52 PM UTC
L
BIIB: pipeline progress and disciplined capital allocation highlighted
BIIB management cited diversification beyond neurology and pipeline momentum, including ten phase III programs, alongside disciplined capital allocation. New launches and acquisitions are set to offset legacy declines, w
EQUITY | Sep 09, 2026, 02:36 PM UTC
M
China NMPA approves subcutaneous lecanemab for early Alzheimer’s
Eisai and Biogen said China’s NMPA approved a lecanemab subcutaneous formulation for initiation treatment in early Alzheimer’s, using a subcutaneous autoinjector (SC-AI).
GEOPOLITICS | Sep 08, 2026, 07:47 PM UTC
M
Canada drug agency gives final positive reimbursement recommendation for lecanemab
Eisai and Biogen said Canada’s Drug Agency (CDA-AMC) issued a final recommendation supporting public reimbursement of LEQEMBI (lecanemab) for eligible early Alzheimer’s disease patients in Canada.
EQUITY | Sep 08, 2026, 03:10 PM UTC
L
Stoke and Biogen present long-term Zorevunersen data at EEC
Stoke Therapeutics and Biogen announced presentations of long-term clinical data supporting the disease-modifying potential of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy
GEOPOLITICS | Sep 03, 2026, 11:30 PM UTC
L
Biogen price target raised to $245 from $225 by Piper Sandler
Piper Sandler raised its price target on Biogen to $245.00 per share from $225.00, according to Benzinga ratings actions.
EQUITY | Sep 03, 2026, 05:42 PM UTC
L
Stoke and Biogen to present Zorevunersen clinical data at EEC
Stoke Therapeutics and Biogen announced presentations of clinical data from studies of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in September.
GEOPOLITICS | Sep 01, 2026, 11:30 AM UTC
L
Leqembi Iqlik autoinjector available in U.S. for early Alzheimer’s
Leqembi Iqlik autoinjector for initiation of therapy is now available in the U.S. for early Alzheimer’s disease.
EQUITY | Aug 27, 2026, 06:58 PM UTC
L
Biogen’s Leqembi iqlik autoinjector available in U.S. for early Alzheimer’s
Eisai and Biogen said the Leqembi iqlik (lecanemab-irmb) autoinjector is now available in the U.S. to initiate therapy for early Alzheimer’s disease.
EQUITY | Aug 24, 2026, 12:02 PM UTC
M
Biogen's Leqembi Iqlik autoinjector now available in U.S.
Biogen says the LEQEMBI IQLIK autoinjector for initiation of therapy is now available in the U.S. for early Alzheimer’s disease.
REGULATION | Aug 24, 2026, 12:01 PM UTC
H
Biogen Acquires RayThera Inc
Biogen completes acquisition of RayThera
MNA | Aug 06, 2026, 10:15 PM UTC
H
US FDA Sets August PDUFA Dates
FDA sets PDUFA dates for several biotech companies
REGULATION | Jul 30, 2026, 03:53 PM UTC
H
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Biogen Inc. (NASDAQ: BIIB ) stock is trading higher on Wednesday after the company reported second-quarter adjusted earnings of $3.60 per share, beating the consensus of $2.96. Revenue Tops Expectations On Growth Across
EARNINGS | Jul 29, 2026, 05:36 PM UTC
H
Biogen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guida
Biogen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance above estimates. Also, Barclays raised its price target on the stock from $1
EARNINGS | Jul 29, 2026, 03:27 PM UTC
H
CORRECTION: Biogen Raises FY2026 Adj EPS Guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 Est
Biogen (NASDAQ: BIIB ) raises FY2026 Adj EPS guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 analyst estimate..
EARNINGS | Jul 29, 2026, 01:12 PM UTC
M
Biogen to be less intentional about M&A
Biogen adopts opportunistic M&A approach
MNA | Jul 29, 2026, 12:42 PM UTC
L
BIIB Biogen - middle East conflict did not have any material effects on our results of operations for three and six months ended June 30, 20
BIIB Biogen - middle East conflict did not have any material effects on our results of operations for three and six months ended June 30, 2026
EQUITY | Jul 29, 2026, 10:43 AM UTC
M
BIIB: No Refund Recorded for IEEPA Tariffs
BIIB doesn't record tariff refund receivable
EQUITY | Jul 29, 2026, 10:41 AM UTC
M
Biogen: Tariffs Won't Hurt 2026 Operations
Biogen expects no material impact from tariffs
EQUITY | Jul 29, 2026, 10:40 AM UTC
H
BIIB Q2 EPS $3.60 vs. est. $2.95; Q2 revs $2.736B vs. est. $2.46B; lowers FY26 EPS view to $12.00-$13.00 from $14.25-$15.25 (est. $12.72); F
BIIB Q2 EPS $3.60 vs. est. $2.95; Q2 revs $2.736B vs. est. $2.46B; lowers FY26 EPS view to $12.00-$13.00 from $14.25-$15.25 (est. $12.72); FY revs now expected to increase by a mid-single digit percentage for 2026 as com
EARNINGS | Jul 29, 2026, 10:19 AM UTC
H
Biogen Lowers FY2026 Adj EPS Guidance from $14.25-$15.25 to $12.00-$13.00 vs $12.83 Est
Biogen (NASDAQ: BIIB ) lowers FY2026 Adj EPS guidance from $14.25-$15.25 to $12.00-$13.00 vs $12.83 analyst estimate..
EARNINGS | Jul 29, 2026, 10:16 AM UTC
H
Biogen 2Q Rev $2.74B, Est. $2.47B
Biogen beats revenue estimates
EARNINGS | Jul 29, 2026, 10:06 AM UTC
H
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.8%, GD +/-3.7%, TEVA +/-6.5%, JCI +/-7.8%, CTSH +/-11.7%, ODFL +/-8.3%, ETR +/-4
EARNINGS | Jul 28, 2026, 06:05 PM UTC
H
BIIB Earnings pre-market tomorrow: qtr EPS est $2.99 (high $3.80/low $1.67), 30-day avg EPS revision -7.3% (3 analyst(s) revised up, 18 down
BIIB Earnings pre-market tomorrow: qtr EPS est $2.99 (high $3.80/low $1.67), 30-day avg EPS revision -7.3% (3 analyst(s) revised up, 18 down), qtr revs est $2.45B; FY EPS est $12.91, FY revs est $10.03B; short interest 4
EARNINGS | Jul 28, 2026, 04:12 PM UTC
L
DNLI Unwarranted Selloff in Sympathy to BIIB's Tau ASO for Alzheimer's; raise PT to $35 from $31 @ DBAB
DNLI Unwarranted Selloff in Sympathy to BIIB's Tau ASO for Alzheimer's; raise PT to $35 from $31 @ DBAB
EQUITY | Jul 16, 2026, 12:10 PM UTC
H
Midday Fly By: IBM warns on Q2 outlook, Goldman reports sharp beat
Stocks moved higher after softer inflation data shut the door on a Fed rate hike this month. Both headline and core inflation rates declined, easing the impact of another rally in energy prices after the U.S. and Iran ma
CENTRAL_BANK | Jul 14, 2026, 04:00 PM UTC
L
BIIB -7% after saying its experimental Alzheimer's drug diranersen missed the main goal of its mid-stage study, which tested whether higher
BIIB -7% after saying its experimental Alzheimer's drug diranersen missed the main goal of its mid-stage study, which tested whether higher doses provided greater benefit in patients with early Alzheimer's Disease; said
EQUITY | Jul 14, 2026, 01:44 PM UTC
L
BIIB -6.2% after Co's experimental Alzheimer's drug misses main goal in mid-stage study
BIIB -6.2% after Co's experimental Alzheimer's drug misses main goal in mid-stage study
EQUITY | Jul 14, 2026, 01:39 PM UTC
L
BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early
BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early alzheimer’s disease Biogen - to advance diranersen into confirmatory phase 3 de
EQUITY | Jul 14, 2026, 01:15 PM UTC
L
Biogen Gets FDA Approval for Leqembi Iqlik as Initiation Dose for Early Alzheimer's Disease
() -- Biogen (BIIB) and Eisai said late Monday that the US Food and Drug Administration has approved a supplemental biologics license application for Leqembi Iqlik, a once-weekly subcutaneous injection, as an initiation
REGULATION | Jul 13, 2026, 10:02 PM UTC
L
BIIB - PR: FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease -LEQEMBI
BIIB - PR: FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease -LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home
REGULATION | Jul 13, 2026, 09:45 PM UTC
L
FDA approves first at-home starting dose for subcutaneous Leqembi
The U.S. Food and Drug...
EQUITY | Jul 13, 2026, 05:40 PM UTC
L
American Express, Biogen upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: JPMorgan upgraded American Express
EQUITY | Jul 13, 2026, 01:43 PM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC
H
Biogen price target raised to $242 from $227 at RBC Capital
RBC Capital raised the firm's price target on Biogen to $242 from $227 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up c
EQUITY | Jul 07, 2026, 11:21 AM UTC
L
Biogen price target raised to $157 from $150 at HSBC
HSBC analyst Morten Herholdt raised the firm's price target on Biogen to $157 from $150 and keeps a Reduce rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector'
EQUITY | Jul 06, 2026, 02:20 PM UTC
L
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
2026-07-04 04:22:00 ET Biogen (NASDAQ: BIIB) built itself into a biotech giant thanks to its port
EQUITY | Jul 04, 2026, 08:25 AM UTC
H
Biogen shares are trading higher after the company issued Q2 in-process research and development guidance.
Biogen shares are trading higher after the company issued Q2 in-process research and development guidance.
EARNINGS | Jul 02, 2026, 03:04 PM UTC
H
Biogen Expects $164M Q2 2026 And $290M-$320M Q3 2026 IPR&D And Milestone Charges, Impacting Earnings By $0.95 And $1.75–$1.95 Per Share, Res
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a p
EARNINGS | Jul 01, 2026, 08:27 PM UTC
M
Biogen: Key Takeaways From Needham’s Meeting With Top Management
Needham analyst Ami Fadia raised her price target on Biogen (NASDAQ: BIIB ) to $256 from $255 and maintained a Buy rating following a meeting with company management. Spinraza HD uptake has been “quite positive,” with de
MNA | Jun 29, 2026, 03:27 PM UTC